The anticancer efficacy of TNF-related apoptosis-inducing ligand (TRAIL)-based therapy is limited because of systemic toxicity, poor bioavailability, and development of TRAIL resistance. We developed a tumor-targeted LCPP (lipid/calcium/phosphate/protamine) nanoparticle (NP) to deliver TRAIL plasmid DNA (pDNA) into hepatocellular carcinoma (HCC) cells in a mouse model of HCC. TRAIL pDNA was encapsulated in a pH stimuli-responsive calcium phosphate (CaP) core, and protamine was added to facilitate nuclear delivery of pDNA. 
1
Jiantai Timothy Qiu, [3] [4] [5] Sheng-Kai Wang, 6 Chu-Chi Lin, 5 Chien-Hsun Wu, 7 Han-Chung Wu, 7 Jia-Yu Liu, 1 and Yunching Chen 1 The anticancer efficacy of TNF-related apoptosis-inducing ligand (TRAIL)-based therapy is limited because of systemic toxicity, poor bioavailability, and development of TRAIL resistance. We developed a tumor-targeted LCPP (lipid/calcium/phosphate/protamine) nanoparticle (NP) to deliver TRAIL plasmid DNA (pDNA) into hepatocellular carcinoma (HCC) cells in a mouse model of HCC. TRAIL pDNA was encapsulated in a pH stimuli-responsive calcium phosphate (CaP) core, and protamine was added to facilitate nuclear delivery of pDNA. In addition, intracellular release of Ca 21 from the CaP core overcame TRAIL resistance by calcium influx-dependent DR5 up-regulation. TRAIL expression also attenuated fibrosis in liver tissues surrounding HCCs by reverting activated hepatic stellate cells (HSCs) to a quiescent state or by directly inducing apoptosis in activated HSCs. Conclusion: TRAIL pDNA delivered by HCC-targeted LCPP NPs in combination with conventional sorafenib treatment attenuated HCC progression as well as liver fibrosis. Overall, our study presents an effective TRAIL-based cancer therapy that could be developed for clinical applications. (HEPATOLOGY 2018;67:899-913).
SEE EDITORIAL ON PAGE 826
T NF-related apoptosis-inducing ligand (TRAIL) exhibits a profound cytotoxic effect in various cancer cells, which calls for the development of TRAIL-receptor agonists for anticancer therapy. (1, 2) TRAIL secreted from natural killer (NK) cells binds to death receptors (death receptor 4 [DR4] or death receptor 5 [DR5]). (3) Following recruitment of procaspase-8 to the adaptor Fas-associated death domain (FADD), the initiator, caspase-8, is activated, resulting in onset of extrinsic and intrinsic apoptosis mediated by activation of caspase-3. (4) Unfortunately, TRAIL-based cancer therapy, such as recombinant TRAIL or agonistic monoclonal antibodies against death receptors, failed to show clinical efficacy in phase II clinical studies. (5, 6) Efficacy of TRAIL-based cancer therapy is often limited because of the short plasma half-life of recombinant Abbreviations: ALP, alkaline phosphatase; ALT, alanine aminotransferase; AST, aspartate aminotransferase; CaMKII, calmodulin-dependent protein kinase II; CaP, calcium phosphate; Cy5, cyanine 5; DOPA, 1,2-dioleoyl-sn-glycero-3-phosphate; DOTAP, 1,2-dioleoyl-3-trimethylammonium-propane; DR5, death receptor 5; DSPE, 1,2-distearoyl-sn-glycero-3-phosphoethanolamine; ECM, extracellular matrix; EGFP, enhanced green fluorescent protein; FADD, Fas-associated death domain; HCC, hepatocellular carcinoma; H&E, hematoxylin-eosin; HF, hepatic fibrosis; HSCs, hepatic stellate cells; LC, liver cirrhosis; LCPP, lipid/calcium/phosphate/protamine; LF, liver fibrosis; luc, luciferase; MAL, maleimide; NP, nanoparticle; NK cells, natural killer cells; pDNA, plasmid DNA; PEG, polyethylene glycol; PEI, polyethyleneimine; a-SMA, alpha-smooth muscle actin; STAT3, signal transducer and activator of transcription 3; TEM, transmission electron microscopy; TRAIL, TNF-related apoptosis-inducing ligand.
TRAIL, unwanted systemic toxicity, low bioavailability in tumor tissues, and treatment evasion resulting from down-regulation of death receptors or activation of antiapoptotic proteins. (5) Thus, use of TRAIL as a cancer therapy awaits further studies to overcome these toxicity and efficacy hurdles.
In place of systemic administration of recombinant proteins, intratumoral or systemic TRAIL gene transfer therapy represents an alternative approach to TRAILbased anticancer therapy. (7) (8) (9) A variety of gene delivery vectors with improved gene transfer efficiency and minimal unwanted toxicity and immunogenicity have been developed for TRAIL gene delivery alone or in combination with chemotherapy drugs to induce synergistic cytotoxicity against cancer cells.
( [10] [11] [12] Cationic polymers, such as polyethyleneimine (PEI), and dendrimers and liposomes have shown potent TRAIL gene transfection efficacy, leading to apoptosis induction in transfected cancer cells. (10, 13) Furthermore, multifunctional nanoparticles (NPs) have been established as carriers to increase tumor-targeted delivery of TRAIL DNA as well as to introduce coformulated chemotherapeutic agents to induce synergistic anticancer effects or contrast agents to provide theranostic benefits. (14) In summary, an optimal gene delivery system needs to meet multiple criteria, including a high DNA-loading capacity, high serum stability, the ability to be selectively taken up into the cells of interest, the ability to efficiently escape endosomal capture and enhance the nuclear import of cargo genes, and the capability to induce sustained transcriptional activity. With this in mind, we developed a TRAIL-based therapeutic NP formulation with a safe and efficient anticancer effect. This nanoscale TRAIL-based gene therapy is a highly efficient gene delivery vector that exhibits multifunctional characteristics, including (1) a pH stimuliresponsive calcium phosphate (CaP) core that also contains protamine, which acts as a nuclear localization signal for TRAIL-gene transfection, (2) calcium ions (derived from the CaP core) that can be released by the NPs to overcome TRAIL resistance, and (3) a hepatocellular carcinoma (HCC)-targeting peptide (SP94) that enhances the selective uptake of the NPs by cancer cells, leading to high bioavailability in tumor tissues.
HCC is characterized as a malignant disease that progresses rapidly, and it is refractory to conventional chemotherapy, as well as molecular targeted therapy. (15, 16) In addition, most cases of HCC develop in the presence of liver cirrhosis (LC) and chronic inflammation, which fuels HCC growth and influences treatment prognosis. (17) (18) (19) (20) (21) A few studies have demonstrated that TRAIL not only promotes apoptosis in cancer cells, but also triggers the resolution of inflammation by inducing apoptosis in neutrophils. (22) In addition, it ameliorates fibrosis by targeting activated myofibroblasts. (23) Given the anticancer, antifibrotic, and anti-inflammatory properties of TRAIL, we investigated whether a multifunctional NP can specifically deliver TRAIL plasmid DNA (pDNA) into HCC cells and efficiently induce TRAIL-mediated apoptosis. Furthermore, we examined whether TRAIL pDNA delivered by HCC-targeted NPs ameliorated liver fibrosis (LF) and suppressed HCC progression with or without the combination of sorafenib-the standard systematic chemotherapy drug for the treatment of advanced HCC-in a clinically relevant HCC model with associated underlying LF. (20) 
Materials and Methods

PREPARATION AND CHARACTERIZATION OF LCPP
NPs LOADED WITH pDNA LCPP NPs were prepared using a modified protocol. (24, 26) Two separate microemulsions (3 mL each)
were prepared. To prepare the calcium-loaded microemulsion, pDNA (15 lg), protamine (7.5 lg), and 40 lL of 500 mM of CaCl 2 (pH 7) were added to the oil phase of cyclohexane and Igepal-520 (7:3, v/v :-cholesterol 5 1:1:2 molar ratio) was added into the CaP cores (2.5:1 ratio of total free lipids to DOPA) and then dried under N 2 . After evaporating the chloroform, 160 lL of water was added to form LCPP NPs. For peptide conjugation, peptide was reduced using immobilized tris(2-carboxyethyl)phosphine disulfide-reducing gel (Thermo Scientific, Rockford, IL), according to the manufacturer's recommendations. SP94 peptides were added into LCPP NPs where they reacted with DSPE-PEG(2000)-maleimide on the surface of the NPs. Four hours later, the unreacted MAL groups were quenched by adding Lcysteine.
IN VIVO HCC MODELS
For the murine orthotopic HCC models, HCA-1 cells were orthotopically implanted into livers of 7-to 8-week-old male mice in a 100 lL of Matrigel solution. To establish the clinically relevant murine HCC model with associated underlying LF, we first treated 5-weekold male C3H mice with CCl 4 (16% v/v in olive oil, 100 lL by gavage, 3 times per week) before tumor implantation/induction. HCA-1 cells were orthotopically implanted in mice 2 weeks after the last CCl 4 treatment, as described (Supporting Fig. S10 ). (25) All experiments were performed in accord with the relevant guidelines and regulations. All animals received humane care in compliance with the Guide for the Care and Use of Laboratory Animals published by the National Academy of Sciences, and all study procedures and protocols were approved by the Animal Research Committee of National Tsing-Hua University (Hsinchu, Taiwan).
Tumor Growth Inhibition Study
Orthotopic HCA-1 tumor-bearing mice were intravenously injected with different formulations containing TRAIL pDNA (0.7 mg/kg/dose, 3 doses per week). Sorafenib (Nexavar, Bayer Schering Pharma) was administered to mice daily by gavage at a dose of 40 mg/kg body weight in combination with TRAIL treatment. Tumor size in treated mice was measured 2 weeks after the first treatment.
To evaluate the antifibrotic effect of the combined sorafenib and TRAIL treatment, sorafenib was given orally and TRAIL pDNA in LCPP NPs was administered intravenously to mice with orthotopic HCA-1 HCCs with associated CCl 4 -induced LF. Tumor size and changes in fibrotic liver tissues surrounding HCC were evaluated after 2 weeks of treatment (Supporting Fig. S10 ).
STATISTICAL ANALYSIS
Data analyses were performed using the MannWhitney U test and Student t test. P values <0.05 were considered statistically significant for all tests.
Results
PREPARATION AND CHARACTERIZATION OF PLASMID DNA-LOADED, HCC-TARGETED MEMBRANE-CORE NPs
Preparation and proposed structure of the DNAloaded, HCC-targeted NPs are shown in Fig. 1A . First, the protamine/nucleic acid (therapeutic plasmid DNA) complex was prepared by mixing protamine and the nucleic acids at a weight ratio of approximately 1:2. We utilized a reverse microemulsion containing Igepal-520 as a surfactant to entrap the protamine/nucleic acid complex in DOPA-coated CaP NPs, as described by Li et al. (26) Next, the DOPA-coated protamine/nucleic acid/CaP NPs were allowed to form a self-assembled lipid-bilayer structure, adding the outer leaflet lipids (DOTAP, cholesterol, DSPE-PEG) to the cores. To enhance HCC uptake, NPs were modified with the HCC-targeting peptide, SP94. Transmission electron microscopy (TEM) images show that the final LCPP (lipid/calcium/phosphate/protamine) NPs were spherical (Fig. 1A) . The characteristics of the LCPP NPs are summarized in Fig. 1B . The average LCPP NP diameter was 102.9 6 7.4 nm, with a zeta-potential of approximately 6 mV. The particle sizes of the LCPP NPs (NPs with protamine) and LCP NPs (NPs without protamine) were similar. The intensity size distributions from LCP-NP and LCPP-NP in water are shown in Supporting Fig. S1 . The percentage of pDNA encapsulation in the LCPP NPs was 93%, which was slightly higher than that in the LCP NPs (86%), indicating that the addition of protamine may improve the efficiency of pDNA encapsulation.
TARGETED DELIVERY OF pDNA USING SP94-TARGETED LCPP NPs EXHIBITED EFFICIENT NUCLEAR UPTAKE OF pDNA AND POTENT TRANSFECTION ACTIVITY IN HCC CELLS IN VITRO AND IN VIVO
Protamine, an arginine-rich DNA condenser, can facilitate endosomal escape and nuclear delivery of condensed DNA. In the present study, the cellular uptake and nuclear delivery of cyanine 5 (Cy5)-labeled pDNA condensed by protamine in LCPP NPs were investigated. The in vitro uptake of fluorescently labeled pDNA was much greater in both human (Hep3B) and murine (HCA-1) HCC cells when delivered by SP94-targeted LCPP NPs than when cells were treated with nontargeted LCPP NPs ( Fig. 2A,B ). The uptake of pDNA delivered by SP94-LCPP in normal mouse FL83B liver cells was minimal (Supporting Fig. S2 ). Furthermore, we observed strong cytoplasmic and nuclear distribution of pDNA co-encapsulated with protamine in SP94-LCPP NPs (Fig. 2C ). SP94-targeted LCP NPs without encapsulated protamine were taken up into HCC cells, but were primarily distributed in the cytoplasm ( Fig. 2A) .
Next, we investigated the impact of protamine on gene transfection activity. Plasmids encoding firefly luciferase (luc) driven by the cytomegalovirus promoter were loaded in different formulations as quantitative reporters of gene expression. The luc pDNA delivered by SP94-targeted LCPP NPs showed significant luciferase expression in both human (Hep3B, JHH-7) and murine (HCA-1) HCC cells (Fig. 3A) . Codelivery with protamine dramatically increased luciferase expression in HCC cells compared with SP94-LCP NPs (without protamine; Fig. 3A ). By contrast, free luc pDNA or luc pDNA formulated in nontargeted NPs did not affect expression of luc in HCC cells (Fig.  3A) . Furthermore, luc pDNA delivered by SP94-NPs with or without protamine only yielded minimal levels of luc expression in normal mouse FL83B liver cells, indicating their selective delivery toward HCC cells relative to normal cells (Fig. 3A) . In summary, we observed strong cytoplasmic and nuclear distribution of pDNA co-encapsulated with protamine in SP94-LCPP NPs, as illustrated in Fig. 3B , indicating that arginine-rich protamine exerted a synergistic effect with CaP on endosomal lysis, facilitating delivery of pDNA into the nucleus and achieving high transfection efficacy.
We next tested in vivo transfection efficiency in orthotopic HCA-1 tumor models. Gene expression and activity were evaluated in the major organs 48 hours after intravenous injection of luc pDNA loaded in different formulations. Gene expression was relatively low in the heart, spleen, kidney, and lung (Fig.  3C,D) . All the formulations showed moderate gene transfection efficacy in the liver (Fig. 3C,D and Supporting Fig. S3 ). By contrast, SP94-targeted LCPP NPs exhibited higher gene transfection efficacy in tumor tissues than nontargeted LCPP NPs (Fig.  3C,D) . In addition, co-encapsulation with protamine (SP94-LCPP) significantly increased gene expression compared with targeted LCP without protamine (SP94-LCP; Fig. 3C,D) . Our results indicated that the SP94-LCPP NPs efficiently delivered pDNA into HCC cells and achieved significant gene expression in vitro and in vivo. In addition, both cell delivery and transfection were enhanced by modification with the HCC-specific ligand (SP94) and co-encapsulation of protamine (Fig. 3B) . only minimal levels of TRAIL (Fig. 4A) . Control enhanced green fluorescent protein (EGFP) pDNA delivered by SP94-LCPP NPs did not increase expression of TRAIL in HCC cells (Fig. 4A) . Our results indicated that the HCC-targeted SP94-LCPP NPs, which efficiently delivered TRAIL pDNA into HCC cells, can achieve a significant level of TRAIL expression. Moreover, HCC cells treated with TRAIL pDNA in SP94-LCPP NPs not only expressed fulllength TRAIL, but also secreted TRAIL into medium (Fig. 4B) . However, the therapeutic efficacy of TRAIL may be limited because of the development of resistance through a variety of mechanisms, such as the down-regulation of the TRAIL death receptor DR5 in cancer cells. It has been reported that calcium signaling increases DR5 expression through activation of calmodulin-dependent protein kinase II (CaMKII) and SP1 and thus overcomes the resistance to TRAIL-induced cell death in HCC cells. (27) We further examined whether the intracellular release of Ca 21 from LCP nanoparticles can trigger calcium influx-dependent DR5 up-regulation through CaMKII activation. SP94-LCPP NPs significantly increased DR5 expression in a dosedependent manner in both human (Hep3B, JHH-7) and murine (HCA-1) HCC cells (Fig. 4C) . To determine whether calcium/CaMKII signaling mediates these effects, we treated JHH-7 cells with SP94-LCPP NPs in the presence of different concentrations of a CaMKII inhibitor, starting at zero (Fig. 4D) . Inhibition of CaMKII prevented the effects of LCPP NPs on DR5 up-regulation in HCC cells, indicating that the enhanced DR5 expression was mediated by the calcium/CaMKII signaling pathway activated by Ca 21 released from LCP NPs (Fig. 4D) .
Next, we evaluated whether TRAIL expression mediated by TRAIL pDNA-loaded SP94-LCPP NPs exerted cytotoxic effects on HCC cells. In HCC cells treated with TRAIL pDNA loaded in SP94-LCPP NPs, cytotoxicity was higher (Fig. 4E ) compared with cells treated with TRAIL pDNA loaded in nontargeted LCPP NPs. The control EGFP pDNA loaded in SP94-LCPP NPs showed no significant cytotoxicity to HCC cells (Fig. 4E) . We next determined whether TRAIL pDNA delivered by HCC-targeted LCPP exerted minimal hepatotoxicity in vitro. Only minimal toxicity was observed in normal mouse FL83B liver cells after directly treated with TRAIL pDNA in SP94-LCPP NPs or indirectly exposed to conditioned medium from HCC cells treated with TRAIL pDNA in SP94-LCPP NPs, indicating that TRAIL pDNA delivered by SP94-LCPP NPs specifically eliminated tumor cells while sparing normal cells (Fig. 4F and Supporting Fig. S5 ). CaMKII blockade rescued cytotoxicity in HCC cells treated with TRAIL pDNA loaded in SP94-LCPP NPs, implying that the up-regulation of DR5 by Ca 21 released from LCP NPs potently sensitizes HCC cells to TRAILinduced apoptosis (Fig. 4F) .
To expand the potential clinical applications, we further studied the cytotoxic effects of TRAIL pDNA-loaded SP94-LCPP NPs in combination with sorafenib, a standard treatment for advanced HCC. It has been shown that sorafenib can sensitize resistant HCC cells to TRAIL-induced apoptosis. (28, 29) To investigate the combined effects of sorafenib and TRAIL on HCC cells, we examined the effects of TRAIL pDNA loaded in SP94-LCPP NPs and sorafenib on cell viability in both human and mouse HCC cell lines at clinically relevant concentrations. Our data showed that treatment with sorafenib at a low dose was insufficient to kill HCC cells (Fig. 5) . However, the combination of sorafenib and TRAIL pDNA delivered by SP94-LCPP NPs achieved an enhanced cytotoxic effect on HCC cells (Fig. 5) . Sensitization of HCC cells to TRAILinduced apoptosis by sorafenib may be due to sorafenib-mediated inhibition of signal transducer and activator of transcription 3 (STAT3; Supporting  Fig. S6 ).
TRAIL pDNA DELIVERED BY SP94-LCPP NPs SIGNIFICANTLY INCREASED TRAIL EXPRESSION IN HCC CELLS IN VIVO AND SUPPRESSED PRIMARY HCC GROWTH AND DISTAL METASTASIS
We further evaluated the effects of TRAIL pDNA delivered by SP94-LCPP NPs on TRAIL expression and induction of apoptosis in HCA-1-transplanted HCC models (Supporting Fig. S7 ). Systemic injections of TRAIL pDNA in SP94-LCPP NPs significantly increased TRAIL expression in HCA-1 tumors, whereas TRAIL expression in tumor tissues remained unchanged after treatment with control EGFP pDNA delivered by SP94-LCPP NPs (Fig. 6A,C) . Only a minimal change in TRAIL expression was observed in LIU, CHERN, ET AL.
tumor tissues treated with TRAIL pDNA in nontargeted LCPP NPs (Fig. 6A,C) . To this end, we next evaluated whether the enhanced TRAIL expression achieved by NPs resulted in increased tumor cell death. We found that TRAIL pDNA delivered by SP94-LCPP NPs significantly increased the number of apoptotic cells in orthotopic HCA-1 tumors compared to the other treatments (Fig. 6B,C) . Moreover, when NP-induced TRAIL expression was combined with sorafenib, it triggered even higher levels of apoptosis in HCC cells compared to the single treatments (Fig. 6B,C) . Thus, induction of TRAIL expression in HCC cells through delivery of TRAIL pDNA by SP94-LCPP NPs leads to tumor apoptosis and may lead to tumor growth inhibition. Indeed, tumor growth inhibition was observed after treatment with TRAIL pDNA in SP94-LCPP NPs in the HCA-1 orthotopic model (Fig. 6D) . Control EGFP pDNA in SP94-LCPP NPs or TRAIL pDNA in nontargeted NPs did not lead to significant HCC growth inhibition (Fig. 6D) . In the orthotopic HCA-1 model, mice developed detectable spontaneous lung metastases approximately 4 weeks after tumor implantation. We further demonstrated that SP94-LCPP NPs carrying TRAIL pDNA significantly inhibited metastasis formation in lungs of HCA-1 orthotopic models (Fig. 6E,F) . In addition, TRAIL pDNA in SP94-LCPP NPs synergistically suppressed primary tumor growth and distal metastasis in HCC when combined with sorafenib (Fig. 6E,F 
-INDUCED LF
Most patients with HCC have LC, liver cirrhosis. (30) The fibrotic microenvironment in a cirrhotic liver may play a crucial role in HCC progression. (15, 17) In addition, the degree of hepatic fibrosis (HF) also impedes the efficacy of HCC treatment attributed to impaired drug delivery and metabolism and stromamediated treatment resistance. It has been shown that activated hepatic stellate cells (HSCs)-the main matrix-producing cells in the progression of LF-overexpress death receptors and are sensitive to TRAILinduced cell death (Supporting Fig. S8) . (31) To determine whether increased TRAIL expression in HCC cells could mediate a decrease in the LF associated with HCC, we first exposed primary HSCs to conditioned medium from HCC (HCA-1) cells treated with different formulations. We found that the conditioned medium from HCA-1 cells treated with TRAIL pDNA-loaded SP94-LCPP NPs significantly decreased HSC viability and inhibited alpha-smooth . (E,F) The number of lung metastatic nodules was significantly reduced in mice treated with TRAIL pDNA delivered by SP94-targeted LCPP NPs. Scale bar 5 50 lm. The data are the mean value 6 the SEM. *P < 0.05; **P < 0.01; ***P < 0.001. Abbreviations: SOR, sorafenib; TUNEL, terminal deoxynucleotidyl transferase dUTP nick end labeling. muscle actin (a-SMA) expression in HSCs compared to the medium conditioned by HCC cells treated with EGFP pDNA-loaded SP94-LCPP NPs, indicating that HCC cells treated with TRAIL pDNA-loaded SP94-LCPP NPs exhibited up-regulated TRAIL expression and produced TRAIL protein, which reduced the survival and activation of HSCs (Fig.  7A,B and Supporting Fig. S9 ). We next evaluated the effect of TRAIL pDNA-loaded SP94-LCPP NPs on desmoplasia in HCC. Treatment of TRAIL pDNAloaded SP94-LCPP NPs reduced expression of intratumoral collagen I and a-SMA 1 myofibroblasts infiltration in orthotopic HCA-1 HCCs (Fig. 7C) .
Furthermore, we examined the antifibrotic and anticancer activities of TRAIL pDNA delivered by SP94-LCPP NPs in a clinically relevant HCC model with associated underlying LF. We first induced LF in mice by tetrachloromethane (CCl 4 ) treatment for 8 weeks and then generated orthotopic tumors through intrahepatic HCA-1 cell implantation in C3H mice (Supporting Fig. S10 ). SP94-LCPP NPs efficiently delivered pDNA into HCC with underlying LF and achieved significant gene expression in vivo (Supporting Fig. S11 ). When tumors became established, we treated mice with TRAIL pDNA in SP94-LCPP NPs in combination with sorafenib for 14 days and then measured the changes in LF and HCC tumor size (Supporting Fig. S10 ). Sorafenib treatment only moderately decreased LF, as measured by collagen I and a-SMA immunostaining ( Fig. 7D and Supporting  Fig. S12 ). Combination treatment with sorafenib and TRAIL pDNA in SP94-LCPP NPs significantly ameliorated LF and inhibited HCC growth in mice with CCl 4 -induced LF (Fig. 7D,E) . Furthermore, the preclinical safety study indicated that serum levels of hepatotoxicity makers, such as aspartate aminotransferase (AST), alanine aminotransferase (ALT), and alkaline phosphatase (ALP), remained the same as the untreated control animals after treatment of TRAIL pDNA in SP94-LCPP NPs (Fig. 8A) . Evaluation of systemic toxicities by hematoxylin-eosin (H&E) staining showing no histopathological changes in the major organs after treatment of SP94-LCPP-TRAIL (Fig. 8B) .
In summary, we have developed HCC-specific SP94-LCPP NPs, in which protamine was incorporated to facilitate the delivery of pDNA into the nucleus, achieving high levels of gene expression in vitro and in vivo. In addition, the SP94 peptide conjugated to the surface of the NPs increased the uptake of NPs by HCC cells. Using this gene delivery system, we delivered TRAIL pDNA into HCC cells and achieved significant cell death. Furthermore, the intracellular release of Ca 21 from the CaP core of the NPs triggered calcium influx-dependent DR5 upregulation in HCC cells and thus overcame TRAIL resistance in HCC cells. Finally, we demonstrated that systemic treatment of TRAIL pDNA delivered by SP94-LCPP NPs could serve as a safe and potent therapeutic approach to suppress HCC progression as well as to attenuate the LF associated with HCC (Fig. 7F) . 
Discussion
Development of TRAIL resistance in cancer cells is the major obstacle to effective TRAIL treatment. Therefore, modulation of the signaling pathways and downstream molecular targets responsible for TRAIL resistance in combination with TRAIL therapy may restore TRAIL sensitivity in cancer cells, enabling TRAIL therapy to serve as an effective anticancer strategy. In this study, we showed that intracellular release of Ca 21 from LCP NPs triggered calcium influx-dependent DR5 up-regulation through CaM-KII activation. Restoration of DR5 expression is effective in overcoming TRAIL resistance in HCC cells. Moreover, we further showed that the addition of sorafenib-the standard first-line therapy for advanced HCC-to TRAIL gene therapy synergistically suppressed HCC progression. Sorafenib displays enhanced anticancer effects attributed to its antiangiogenic property by targeting vascular endothelial growth factor receptor/platelet-derived growth factor receptor and its anti-proliferative property through its ability to block the RAF/mitogen activated protein kinase kinase/extracellular signal-regulated kinase pathway. (32) In addition to its anticancer effect, sorafenib may also play a role in overcoming TRAIL resistance. It has been shown that sorafenib down-regulated phospho-STAT3 and subsequently decreased expression of STAT3 downstream proteins (myeloid cell leukemia, survivin, and cyclin D1), which mediate TRAIL resistance in HCC cells. (29) Therefore, sorafenib sensitizes HCC cells to TRAIL-induced apoptosis through inactivation of the STAT3 signaling pathway. Our results suggest that activation of proapoptotic factors, including up-regulation of death receptors or down-regulation of prosurvival signals, such as STAT3 inactivation, may prime cancer cells for TRAIL-mediated apoptosis.
In addition to its anticancer property, TRAIL also revealed anti-inflammatory and antifibrotic activities in various disease models. (23, 33) In this study, TRAIL pDNA delivered by HCC-targeted LCP NPs increased TRAIL expression in HCC cells. The membrane-bound full-length TRAIL was not only displayed on the cell surface, but also secreted into the culture medium. The release of TRAIL may be mediated by enzymatic cleavage to generate soluble TRAIL or by the secretion of microvesicles loaded with fulllength TRAIL. (34, 35) Both membrane-bound TRAIL and soluble TRAIL can induce apoptosis in HCC cells. (36) TRAIL released by HCC cells not only triggered apoptosis in cancer cells, but also attenuated fibrosis in the liver tissues surrounding HCCs by directly causing cell death in activated HSCs and reverting activated HSCs to a quiescent state, as indicated by the reduced a-SMA expression and extracellular matrix (ECM) deposition. The resolution of LF and tumor desmoplasia may facilitate drug delivery and penetration in HCCs and further delay tumor progression. Notably, we also found that TRAIL pDNA delivered by SP94-LCPP NPs significantly suppressed lung metastasis in orthotopic HCC models. The reduction in metastasis formation after TRAIL treatment may be mediated by the induction of apoptosis in circulating tumor cells lacking integrin-mediated cell adhesion and the depletion or inactivation of cancer-associated fibroblasts that promote the migration and invasion of cancer cells. (37, 38) The desmoplastic stromal barrier blocks effective drug delivery, and tumor-stroma cross-talk influences cancer cell proliferation, metabolism, and metastatic potential, affecting the overall survival of patients with various types of cancer. Therefore, TRAIL pDNA delivered by tumortargeted LCP NPs that promote regression of both desmoplasia and tumors can provide an effective strategy for cancer treatment.
Achieving safe and effective gene therapy for cancer requires developing "smart" nanoparticle delivery systems that can increase the bioavailability of encapsulated genetic material, display stimuli-responsive properties for efficient intracellular release and delivery of therapeutic cargo, reduce side effects, polarize the protumor microenvironment to an antitumor microenvironment, and overcome resistance to gene therapy. There are several advantages of the tumor-targeted LCPP NPs that we developed for delivery of TRAIL pDNA as anticancer agents. (1) A long circulation time and active tumor targeting were achieved by the addition of SP94 peptide-PEG-DSPE on the surface of NPs. (2) The positively charged protamine loaded in the CaP core increased the encapsulation efficacy of pDNA and enhanced the endosomal escape of NPs. Furthermore, co-encapsulation with protamine increased the uptake of pDNA in the nuclei of HCC cells, suggesting that protamine containing a nuclear localization signal could facilitate delivery of pDNA into the nucleus. (3) The acid-sensitive CaP coprecipitated with the DNA/protamine complexes in the membrane-core NPs and triggered the disruption of the endosomes and intracellular release of Ca 21 from CaP cores, which overcame TRAIL resistance and thus potentiated TRAIL-mediated apoptosis in HCC when TRAIL pDNA was delivered. In conclusion, the NPs present multifunctional properties for efficient delivery of TRAIL DNA, resensitization of TRAILresistant cancer cells toward TRAIL-induced apoptosis, and targeting of both the tumor and the adjacent tumor microenvironment, resulting in significant suppression of tumor progression. Our study provides insights into the development of effective TRAILbased cancer therapies that could be developed into a translational platform for clinical applications.
